Name: 글로벌 시장 동향
SKU: PH7169
Availability: InStock

보고서 요약(국문)

개요
전 세계 내장형 리슈마니아증 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
전 세계 내장형 리슈마니아증 치료 시장은 여러 요인의 영향으로 지난 수년간 상당한 성장과 변화를 경험해 왔습니다. 칼라아자르라고도 불리는 내장형 리슈마니아증(VL)은 치료하지 않으면 95% 이상의 환자에게 치명적입니다. 이 질환은 불규칙적인 발열, 체중 감소, 비장과 간 비대, 빈혈 등의 증상을 특징으로 합니다. 브라질, 동아프리카, 인도에서 가장 많은 환자가 발생합니다.
특히 개발도상국을 중심으로 한 정부 투자와 연구는 첨단 제품 또는 치료법의 활용을 촉진하고 전 세계 내장형 리슈마니아증 치료 시장의 성장을 견인할 것입니다. 이러한 혁신적인 제품에는 5가 안티몬 제제와 같은 새로운 치료법을 활용한 효과적인 관리가 포함됩니다.

시장 동향: 성장 동력 및 제약 요인
협력 확대 및 정부 주도 사업
선진국들은 높은 투자, 소득 수준 향상, 인프라 개발에 힘입어 의료 부문이 빠르게 발전하고 있습니다. 여러 국가에서는 연구 결과가 긍정적으로 나타남에 따라 내장형 리슈마니아증 치료제에 대한 수요가 크게 증가했습니다. 각국의 제품 출시 관련 규제 승인은 시장 성장을 견인하는 중요한 요인이 될 것입니다.
2023년 1월 26일, 세계보건기구(WHO)와 길리어드 사이언스(Gilead Sciences)는 내장형 리슈마니아증으로 가장 큰 피해를 입은 국가들에 암비솜(AmBisome, 리포솜 암포테리신 B 주사제) 304,700병을 공급하는 계약을 체결하여 기존 계약을 2025년까지 연장했습니다.

1,130만 달러의 비용이 소요될 것으로 예상되는 새로운 3년 계약(2023-2025)에는 내장형 리슈마니아증 환자 공동체를 위한 더 나은 보장, 접근성 및 치료를 위한 재정 지원도 포함됩니다.
또한, 알파-1 항트립신 결핍증 관리를 위한 새로운 치료법 또는 약물의 사용이 증가하고 있습니다. 사람들의 인식 제고와 혁신적인 제품 개발을 위한 연구 증가는 내장형 리슈마니아증 치료 시장 성장을 이끄는 주요 요인이 될 것입니다.
약물 관련 부작용
발진, 고혈당증, 저마그네슘혈증, 저칼륨혈증, 설사, 구토, 메스꺼움, 빈혈, 알칼리성 인산분해효소 증가, 혈중 요소 질소 수치 증가, 오한, 크레아티닌 증가, 불면증 및 호흡곤란은 모든 연구에서 AmBisome 투여 시 20% 이상의 발생률로 가장 빈번하게 보고된 부작용입니다. 오한/떨림, 메스꺼움, 발열, 구토, 빈맥, 고혈압, 호흡곤란, 저산소증은 주입과 관련된 반응 중 일부입니다.
암비솜 투여는 안면 홍조, 가슴 압박감과 무관한 허리 불편감 또는 흉통과 관련이 있는 경우가 있으며, 드물게 심각한 경우도 있습니다. 이러한 증상이 나타난 경우, 주입 시작 직후에 반응이 나타났고 주입을 중단하면 빠르게 가라앉았습니다. 주입 빈도를 줄이면 이러한 증상은 일반적으로 다음 투여 시 재발하지 않으며 매 투여 시에도 나타나지 않습니다.
세그먼트 분석
전 세계 내장형 리슈마니아증 치료 시장은 약물 유형, 투여 경로, 최종 사용자 및 지역별로 세분화됩니다.
암포테리신 B 리포솜 부문은 시장 점유율의 약 39%를 차지했습니다.
암비솜 주사제는 리슈마니아증을 포함한 심각한 진균 감염 치료에 사용되는 항진균제 계열에 속합니다. 진균 감염은 진균이 조직을 감염시켜 공격하는 질환입니다. 곰팡이는 자연에서 흔히 발견되지만 일반적으로 질병을 일으키지는 않습니다.
하지만 일부 곰팡이는 면역 체계가 약화된 사람에게 감염을 일으킬 수 있습니다. 암비솜 주사제의 성분인 암포테리신 B는 곰팡이의 외막을 파괴하여 곰팡이를 사멸시킵니다. 곰팡이 세포벽은 세포 내용물의 유출과 유해 물질의 세포 내 침투를 막기 때문에 곰팡이의 생존에 매우 중요합니다.
2021년 12월 15일, 미국 식품의약국(FDA)은 선 제약(Sun Pharmaceutical Industries Limited)의 전액 출자 자회사가 제출한 50mg/바이알 암포테리신 B 리포솜 주사제(단회 투여용 바이알)의 신약 허가 신청(ANDA)을 최종 승인했습니다. 이 제네릭 제품 승인의 근거는 암비솜 리포솜 주사제(50mg/바이알)입니다.
암비솜 리포솜 주사제(50mg/바이알)는 이 제네릭 제품 승인의 근거로 사용되었습니다. 미국 FDA는 Sun Pharma에 경쟁 제네릭 치료제(CGT) 분류를 부여했으며, 최초로 승인된 제네릭 의약품으로서 Sun Pharma는 해당 의약품에 대해 180일간의 CGT 독점권을 갖게 됩니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 35%를 차지했습니다.
내장형 리슈마니아증 치료에 대한 의료 수요 증가로 인해 북미 지역 제조업체들은 사업 확장의 기회를 얻고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되어 내장형 리슈마니아증 치료제에 대한 수요를 견인하고 있습니다.
의료비 지출 증가, 연구 활동 확대, 기술 발전, 다양한 치료법 개발, 그리고 이 지역의 제약 및 생명공학 기업 설립 증가는 이 지역의 내장형 리슈마니아증 치료제 시장 점유율 성장에 기여하고 있습니다. 암포테리신 B 리포솜 제제와 같은 다양한 혁신적인 신약 치료법에 대한 인식이 높아짐에 따라 이 지역 시장은 성장하고 있습니다. 앞서 언급한 요소들은 북미가 세계에서 차지하는 패권적 위치를 더욱 뒷받침합니다.
북미는 미국을 중심으로 전 세계 내장형 리슈마니아증 치료 시장에서 핵심적인 역할을 계속하고 있습니다. 인프라 개발 및 투자를 장려하는 정부 정책과 첨단 기술 발전에 대한 집중은 미국 내 내장형 리슈마니아증 치료 수요를 촉진했습니다. 미국은 여러 정책 및 연구를 적극적으로 추진하여 내장형 리슈마니아증 치료 수요를 자극해 왔습니다.
COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 전 세계 내장형 리슈마니아증 치료 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄, 공급망 차질, 경제 활동 감소에 직면하면서 다양한 의료기기의 주요 소비자인 제약 부문은 큰 타격을 입었습니다. 2020년 초부터 시작된 팬데믹의 광범위한 봉쇄와 제한 조치로 인해 전 세계 여러 분야에서 다양한 노력이 영향을 받았습니다.
주요 의료기기 산업은 가동이 중단되고 COVID-19 관리에 집중하면서 내장형 리슈마니아증 치료제 수요가 급감했습니다. 하지만 현재 여러 연구가 시작되었고, 기업들은 제품의 안전성과 효능에 대한 임상 시험을 다시 시작했습니다. 전반적으로 팬데믹이 전 세계 내장형 리슈마니아증 치료 시장에 미치는 영향은 비교적 적을 것으로 예상되며, 항균제 및 기타 리슈마니아증 관리 프로그램과 같은 새로운 치료법에 대한 지속적인 필요성과 연구로 인해 시장은 꾸준히 성장할 것으로 전망됩니다.

주요 동향
• 2023년 3월 30일, 길리어드 사이언스(Gilead Sciences, Inc.)는 저소득 및 중소득 국가에서 크립토코커스 수막염과 내장형 리슈마니아증 치료를 위해 정부 및 공공 부문을 지원하는 기타 비정부 보건기구를 대상으로 암비솜(AmBisome, 암포테리신 B 리포솜 주사제 50mg/바이알)의 무이윤 비용을 재산정할 예정입니다. 이는 길리어드가 해당 국가에서 암비솜의 장기적인 공급 안정성을 보장하기 위한 조치입니다.

• 2022년 9월 29일, 비영리 의료 연구 기관인 소외 질병 치료제 개발 이니셔티브(DNDi)와 협력 기관들은 동아프리카에서 내장형 리슈마니아증 환자를 대상으로 더 짧고 독성이 적은 치료법의 효능을 입증하는 임상 시험을 진행했습니다. 이 새로운 치료법은 주사형 항생제인 파로모마이신(PM)과 리슈마니아증 치료에 사용 가능한 유일한 경구용 약물인 밀테포신(MF)을 병용합니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Merck KGaA, PRG Pharma, LEXICARE PHARMA PVT. LTD., SanMak Pharmaceuticals Private Limited, Pfizer Inc., Avet Pharmaceuticals Inc., Profounda Pharmaceuticals, Knight Therapeutics Inc., Sun Pharmaceutical Industries Ltd. 및 Gilead Sciences, Inc. 등이 있습니다.
보고서 구매 이유

• 약물 유형, 투여 경로, 최종 사용자 및 지역별 글로벌 내장 리슈마니아증 치료 시장 세분화를 시각화하고 주요 상업적 자산 및 업체를 파악하기 위해

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위해

• 모든 세그먼트를 포함한 내장 리슈마니아증 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트

보고서 구매 이유 • PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 내장형 리슈마니아증 치료 시장 보고서는 약 61개의 표, 57개의 그림, 186페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

•

보고서 요약(영어 원문)

Overview
Global visceral leishmaniasis treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global visceral leishmaniasis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Over 95% of cases of visceral leishmaniasis (VL), often known as kala-azar, are fatal if untreated. It is distinguished by irregular fever attacks, weight loss, spleen and liver enlargement, and anemia. Brazil, east Africa, and India account for the majority of instances.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products or therapies and boost the global visceral leishmaniasis treatment market. The respective innovative products includes the use of novel treatments such as pentavalent antimonials for better management.
Market Dynamics: Drivers & Restraints
Growing collaborations and government initiatives
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for visceral leishmaniasis treatment owing to the positive outcomes in research. Various regulatory approvals for product launch among different countries will be a crucial factor driving the growth of the market.
On January 26, 2023, the previous agreement between the World Health Organization (WHO) and Gilead Sciences was extended through 2025 with the signing of another contract for the supply of AmBisome (liposomal amphotericin B injection) 304,700 vials for the management of visceral leishmaniasis in nations most affected by the disease.
The new three-year agreement (2023-2025), which is expected to cost $11.3 million, also includes financial support for better coverage, access, and therapy for visceral leishmaniasis-affected communities.
Furthermore, the rising utilization of novel therapies or drugs for the management of alpha-1 antitrypsin deficiency. Rising awareness among people and increasing research for innovative product development will be a major factor driving the growth of the Visceral Leishmaniasis Treatments market.
Side effects associated with the drugs
Rashes, hyperglycemia, hypomagnesemia, hypokalemia, diarrhea, vomiting, nausea, anemia, raised alkaline phosphatase, higher levels of urea nitrogen in blood, chills, raised creatinine, insomnia, and dyspnea are the most frequently reported adverse reactions with an incidence of >20% with AmBisome across all studies. Chills/rigors, nausea, fever, vomiting, tachycardia, hypertension, dyspnea, and hypoxia are among responses connected to infusions.
The administration of AmBisome has been linked to a few instances of flushing, back discomfort regardless of chest tightness, or chest pain; on occasion, this has become severe. Where these signs were observed, a reaction arose shortly after the infusion began and quickly subsided when it was stopped. When the infusion frequency is lowered, these symptoms normally do not return with consecutive doses and do not happen with every dose.
Segment Analysis
The global visceral leishmaniasis treatment market is segmented based on drug type, route of administration, end user and region.
Amphotericin B Liposomal segment accounted for approximately 39% of market share
Ambisome Injection is a member of the 'antifungal' drug class, which is used for the treatment of severe fungal infections including leishmaniasis. A fungal infection is a condition when fungi infect the tissue and attack it. Although fungi are frequently found in nature, they typically do not cause illnesses.
Some fungi, however, may infect a human if they have a weakened immune system. Amphotericin B, an ingredient in ambisome injection, kills fungus by rupturing their outer cell membrane. Since they inhibit the escape of cell contents and the entry of undesirable substances into the cells, the fungal cell walls are crucial for their survival.
On December 15, 2021, the US FDA has given its final approval to Sun Pharmaceutical Industries Limited's wholly-owned subsidiaries for its abbreviated new drug application (ANDA) for 50 mg/vial amphotericin b liposome generic version for Injection, Single-Dose Vial. AmBisome Liposome Injection, 50 mg/vial is used as the basis for the approval of the generic product.
AmBisome Liposome Injection, 50 mg/vial is used as the basis for the approval of the generic product. The US FDA has given Sun Pharma the classification of competitive generic therapy (CGT), and as the first generic approved, the company is entitled to CGT exclusivity of 180 days for the drug.
Geographical Penetration
North America accounted for around 35% of market share in 2022
Due to the rising need for visceral leishmaniasis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for visceral leishmaniasis treatment.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different kinds of therapies for management, and increase in pharmaceutical or biotechnology business establishment across the region are also contributing to the growth of visceral leishmaniasis treatment market share of this region. The market in this area is growing as people become more aware of various novel innovative therapies such as amphotericin b liposomal. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global visceral leishmaniasis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for visceral leishmaniasis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating visceral leishmaniasis treatment demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global visceral leishmaniasis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for visceral leishmaniasis treatment. Now several research studies have been initiated and companies have again started trial for their products safety and efficacy. Overall, the impact of the pandemic on the global visceral leishmaniasis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel therapies, like antimicrobials and other programs for management of leishmaniasis.
Key Developments
• On March 30, 2023, for the purpose of treating cryptococcal meningitis and visceral leishmaniasis in low- and middle-income nations, Gilead Sciences, Inc. will recalculate the no-profit cost of AmBisome (amphotericin B liposome for injection 50mg/vial) for governments and other non-governmental health organizations serving the public sector. This modification is being made by Gilead to guarantee the long-term viability of the AmBisome supply for the firm's global access initiative in these nations.
• On September 29, 2022, The Drugs for Neglected Diseases initiative (DNDi), a non-profit medical research organization, and its collaborators conducted a trial in Eastern Africa that demonstrated the efficacy of a shorter, less toxic treatment for persons with visceral leishmaniasis. The novel therapy combines paromomycin (PM), an injectable antibiotic, with miltefosine (MF), the only oral medication available to treat leishmaniasis.
Competitive Landscape
The major global players in the market include Merck KGaA, PRG Pharma, LEXICARE PHARMA PVT. LTD., SanMak Pharmaceuticals Private Limited, Pfizer Inc., Avet Pharmaceuticals Inc., Profounda Pharmaceuticals,Knight Therapeutics Inc., Sun Pharmaceutical Industries Ltd. and Gilead Sciences, Inc..
Why Purchase the Report?
• To visualize the global visceral leishmaniasis treatment market segmentation based on drug type, route of administration, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of visceral leishmaniasis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global visceral leishmaniasis treatment market report would provide approximately 61 tables, 57 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Route of Administration
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing collaborations and government initiatives
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Pentavalent Antimonials*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Sodium Stibogluconate (Pentostam)
7.2.4. Meglumine Antimoniate (Glucantim)
7.3. Antimicrobials
7.3.1. Paromomycin
7.3.2. Miltefosine
7.4. Antifungal
7.4.1. Amphotericin B Liposomal
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intravenous
8.4. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Merck KGaA*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. PRG Pharma
12.3. LEXICARE PHARMA PVT. LTD.
12.4. SanMak Pharmaceuticals Private Limited
12.5. Pfizer Inc.
12.6. Avet Pharmaceuticals Inc.
12.7. Profounda Pharmaceuticals
12.8. Knight Therapeutics Inc.
12.9. Sun Pharmaceutical Industries Ltd.
12.10. Gilead Sciences, Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Merck KGaA, 4. Key Developments, PRG Pharma, LEXICARE PHARMA PVT. LTD., SanMak Pharmaceuticals Private Limited, Pfizer Inc., Avet Pharmaceuticals Inc., Profounda Pharmaceuticals, Knight Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Gilead Sciences, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Visceral Leishmaniasis Treatment Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Visceral Leishmaniasis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Visceral Leishmaniasis Treatment Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Visceral Leishmaniasis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Visceral Leishmaniasis Treatment Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Visceral Leishmaniasis Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 7 Global Visceral Leishmaniasis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Visceral Leishmaniasis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Visceral Leishmaniasis Treatment Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Visceral Leishmaniasis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global Visceral Leishmaniasis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Visceral Leishmaniasis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 Global Visceral Leishmaniasis Treatment Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 14 North America Visceral Leishmaniasis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Visceral Leishmaniasis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America Visceral Leishmaniasis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Visceral Leishmaniasis Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 18 South America Visceral Leishmaniasis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Visceral Leishmaniasis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America Visceral Leishmaniasis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Visceral Leishmaniasis Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 22 Europe Visceral Leishmaniasis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Visceral Leishmaniasis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe Visceral Leishmaniasis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Visceral Leishmaniasis Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Visceral Leishmaniasis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Visceral Leishmaniasis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Visceral Leishmaniasis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Visceral Leishmaniasis Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Visceral Leishmaniasis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Visceral Leishmaniasis Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Merck KGaA: Overview

Table 33 Merck KGaA: Product Portfolio

Table 34 Merck KGaA: Key Developments

Table 35 PRG Pharma: Overview

Table 36 PRG Pharma: Product Portfolio

Table 37 PRG Pharma: Key Developments

Table 38 LEXICARE PHARMA PVT. LTD.: Overview

Table 39 LEXICARE PHARMA PVT. LTD.: Product Portfolio

Table 40 LEXICARE PHARMA PVT. LTD.: Key Developments

Table 41 SanMak Pharmaceuticals Private Limited: Overview

Table 42 SanMak Pharmaceuticals Private Limited: Product Portfolio

Table 43 SanMak Pharmaceuticals Private Limited: Key Developments

Table 44 Pfizer Inc.: Overview

Table 45 Pfizer Inc.: Product Portfolio

Table 46 Pfizer Inc.: Key Developments

Table 47 Avet Pharmaceuticals Inc.: Overview

Table 48 Avet Pharmaceuticals Inc.: Product Portfolio

Table 49 Avet Pharmaceuticals Inc.: Key Developments

Table 50 Profounda Pharmaceuticals: Overview

Table 51 Profounda Pharmaceuticals: Product Portfolio

Table 52 Profounda Pharmaceuticals: Key Developments

Table 53 Knight Therapeutics Inc.: Overview

Table 54 Knight Therapeutics Inc.: Product Portfolio

Table 55 Knight Therapeutics Inc.: Key Developments

Table 56 Sun Pharmaceutical Industries Ltd.: Overview

Table 57 Sun Pharmaceutical Industries Ltd.: Product Portfolio

Table 58 Sun Pharmaceutical Industries Ltd.: Key Developments

Table 59 Gilead Sciences, Inc.: Overview

Table 60 Gilead Sciences, Inc.: Product Portfolio

Table 61 Gilead Sciences, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Visceral Leishmaniasis Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 3 Global Visceral Leishmaniasis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Visceral Leishmaniasis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global Visceral Leishmaniasis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Visceral Leishmaniasis Treatment Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 7 Pentavalent Antimonials Drug Type in Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Antimicrobials Drug Type in Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Antifungal Drug Type in Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Global Visceral Leishmaniasis Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 11 Oral Route of Administration in Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Intravenous Route of Administration in Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million

Figure 13 Others Route of Administration in Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Global Visceral Leishmaniasis Treatment Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 15 Hospitals End User in Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Ambulatory Surgical Centers End User in Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Others End User in Global Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Global Visceral Leishmaniasis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 19 North America Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Asia-Pacific Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Europe Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 South America Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Middle East and Africa Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 North America Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 North America Visceral Leishmaniasis Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 26 North America Visceral Leishmaniasis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 27 North America Visceral Leishmaniasis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 28 North America Visceral Leishmaniasis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 29 South America Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 South America Visceral Leishmaniasis Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 31 South America Visceral Leishmaniasis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 32 South America Visceral Leishmaniasis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 33 South America Visceral Leishmaniasis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 34 Europe Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 35 Europe Visceral Leishmaniasis Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 36 Europe Visceral Leishmaniasis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 37 Europe Visceral Leishmaniasis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 38 Europe Visceral Leishmaniasis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 39 Asia-Pacific Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 40 Asia-Pacific Visceral Leishmaniasis Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 41 Asia-Pacific Visceral Leishmaniasis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 42 Asia-Pacific Visceral Leishmaniasis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 43 Asia-Pacific Visceral Leishmaniasis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 44 Middle East & Africa Visceral Leishmaniasis Treatment Market Value, 2021-2030 (US$ Million)

Figure 45 Middle East & Africa Visceral Leishmaniasis Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 46 Middle East & Africa Visceral Leishmaniasis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 47 Middle East & Africa Visceral Leishmaniasis Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 48 Merck KGaA: Financials

Figure 49 PRG Pharma: Financials

Figure 50 LEXICARE PHARMA PVT. LTD.: Financials

Figure 51 SanMak Pharmaceuticals Private Limited: Financials

Figure 52 Pfizer Inc.: Financials

Figure 53 Avet Pharmaceuticals Inc.: Financials

Figure 54 Profounda Pharmaceuticals: Financials

Figure 55 Knight Therapeutics Inc.: Financials

Figure 56 Sun Pharmaceutical Industries Ltd.: Financials

Figure 57 Gilead Sciences, Inc.: Financials

세계 내장형 리슈마니아증 치료 시장 – 2023-2030

Global Visceral Leishmaniasis Treatment Market - 2023-2030